Skip to main content
Premium Trial:

Request an Annual Quote

Lynx Receives Nasdaq Delisting Notice for Failure to Hold Annual Shareholder Meeting

NEW YORK, Jan. 7 (GenomeWeb News) - Lynx Therapeutics announced after market close today that it received a delisting warning from Nasdaq on Jan. 4.


According to the Nasdaq Staff Determination letter, the company's securities are subject to delisting from the Nasdaq SmallCap Market due to its failure to hold an annual meeting of stockholders by Dec. 31, 2004.


Lynx said that it has delayed the annual meeting until a proxy statement filed with the Securities and Exchange Commission on Oct. 29, 2004, has been approved by the SEC. The company said in a statement that it has "tentatively" scheduled its annual meeting for Feb. 17, 2005, in order to approve its proposed merger with Solexa, which it still plans to complete by the end of the quarter.


"We will appeal this decision as we plan to hold an annual meeting of stockholders during the current quarter to vote on our proposed business combination with Solexa," Mary Schramke, Lynx's acting CEO, said in a statement.


The company said that its stock will continue to be listed on the Nasdaq SmallCap Market pending a final ruling of the Nasdaq Listing Qualifications Panel.


Schramke added that the notice "does not come as a surprise as we elected to avoid the costs of holding multiple annual stockholders' meetings in a relatively short time period."


Following the upcoming stockholders' meeting, she said the company will be "in full compliance with Nasdaq listing requirements."


Schramke said that Lynx has filed an application for initial listing of its shares following the merger with Solexa.


Lynx is also struggling to meet a requirement that its stock trade above $4.00 for 90 trading days preceding the merger with Solexa. The company said in SEC filings that its does not currently satisfy the minimum bid price and intends to effect a reverse split of its outstanding shares in order to satisfy these requirements.


The company's shares closed at $3.63 today.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.